Background
Methods
Study design
Measures
Sample size calculation
Statistical analysis
Results
Participant characteristics
Characteristics | Indigenous (n = 16) | Non-Indigenous (n = 385) | p-value |
---|---|---|---|
Age (y) | 63.3 (54.7–67.8) | 69.6 (63.3–75.4) |
0.005
|
Sex (% Males) | 10 (62.5%) | 293 (76.1%) | 0.215 |
Diabetes mellitus | 7 (43.8%) | 103 (26.8%) | 0.135 |
Smoker |
0.041
| ||
Never | 0 (0%) | 82 (21.3%) | |
Current | 9 (56.3%) | 121 (31.4%) | |
Previous | 7 (43.8%) | 182 (47.3%) | |
Hypertension | 15 (93.8%) | 290 (75.3%) | 0.091 |
IHD | 10 (62.5%) | 164 (42.6%) | 0.116 |
Stroke | 1 (6.3%) | 38 (9.9%) | 0.632 |
eGFR (mL/min/1.73m2) | 79.0 (46.5–85.8) [2]a | 78 (60.0–91.0) [93]a | 0.416 |
Medications | |||
Aspirin | 11 (68.88%) | 252 (65.5%) | 0.786 |
Other antiplatelet | 3 (18.8%) | 66 (17.1%) | 0.867 |
Frusemide | 4 (25.0%) | 28 (7.3%) |
0.010
|
ACEI | 10 (62.5%) | 152 (39.5%) | 0.066 |
Beta-Blocker | 6 (37.5%) | 115 (29.9%) | 0.515 |
Calcium channel blocker | 3 (18.8%) | 115 (29.9%) | 0.339 |
Metformin | 4 (25.0%) | 69 (17.9%) | 0.472 |
Insulin | 3 (18.8%) | 20 (5.2%) |
0.022
|
Statin | 13 (81.3%) | 273 (70.9%) | 0.370 |
Characteristics | Indigenous (n = 16) | Non-Indigenous (n = 385) | p-value |
---|---|---|---|
Presentationa | 0.385 | ||
Intermittent Claudication | 8 (50.0%) | 126 (32.7%) | |
Critical Limb Ischemia | 2 (12.5%) | 24 (6.2%) | |
Abdominal Aortic or peripheral aneurysm | 3 (18.8%) | 142 (36.9%) | |
Asymptomatic carotid stenosis | 2 (12.5%) | 46 (11.9%) | |
Symptomatic carotid stenosis | 1 (6.2%) | 47 (12.2%) |
Association between indigenous ethnicity and major cardiovascular events
Unadjusted HR (95%CI) | p-value | Adjusted HR (95%CI) | p-value | |
---|---|---|---|---|
MI, stroke or death | ||||
Non-Indigenous | 1.00 |
–
| 1.00 |
–
|
Indigenous | 3.59 (1.42–9.07) | 0.007 | 3.12 (1.14–8.49) | 0.026 a |
– | – | 4.03 (1.17–13.84) | 0.027 b | |
– | – | 4.72 (1.41–15.78) | 0.012 c |